recurrent squamous cell carcinoma of the larynx
Showing 1 - 25 of >10,000
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous
Recruiting
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- +50 more
- transoral robotic surgery
- quality of life assessment
-
Columbus, OhioOhio State University Medical Center
Oct 28, 2022
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
Active, not recruiting
- Squamous Cell Carcinoma of the Oropharynx
- +7 more
-
Tampa, Florida
- +2 more
Dec 30, 2022
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous
Active, not recruiting
- Metastatic Head and Neck Squamous Cell Carcinoma
- +9 more
- Carboplatin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 27, 2022
Head Neck Cancer Trial in San Diego (Medpulser Electroporation with Bleomycin, Surgical Excision)
Terminated
- Head Neck Cancer
- Medpulser Electroporation with Bleomycin
- Surgical Excision
-
San Diego, CaliforniaInovio Biomedical Corporation
Mar 2, 2022
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- +11 more
- KEYTRUDA®
- (no location specified)
Nov 17, 2023
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma Trial in Gliwice (Chemotherapy
Recruiting
- Squamous Cell Carcinoma of Oral Cavity
- +3 more
- Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
-
Gliwice, Silesia, PolandThe Maria Sklodowska-Curie National Research Institute of Oncolo
Aug 7, 2023
Following Salvage Surgery for RESidual or reCurrent sqUamous
Not yet recruiting
- Head and Neck Cancer
- Molecular Analyses
- (no location specified)
Mar 28, 2023
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell
Completed
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2021
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
- (no location specified)
Aug 17, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx
Not yet recruiting
- Squamous Cell Carcinoma of the Oral Cavity
- +3 more
- Eliminating RT to the elective neck
- RT standard of care
-
Erlangen, Bavaria, GermanyUniversitätsklinikum Erlangen, Strahlenklinik
Sep 8, 2023
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- +2 more
- RP3
- +3 more
- (no location specified)
Feb 21, 2023
Squamous Cell Carcinoma of Larynx Trial in São Paulo (carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v.
Recruiting
- Squamous Cell Carcinoma of Larynx
- carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
- +2 more
-
São Paulo, BrazilBeneficiencia Portuguesa de São Paulo/Hospital São José
Dec 22, 2022
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jun 9, 2023
Squamous Cell Carcinoma Trial (MK-3475A)
Not yet recruiting
- Squamous Cell Carcinoma
- MK-3475A
- (no location specified)
Sep 11, 2023
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,
Not yet recruiting
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Ficlatuzumab
- +2 more
- (no location specified)
Sep 26, 2023
Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Dec 20, 2022
Head and Neck Squamous Cell Carcinoma, PET/CT Trial (Neck dissection)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- PET/CT
- Neck dissection
- (no location specified)
Jan 31, 2023
Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)
Not yet recruiting
- Head Neck
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 14, 2023
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2023